Introduction ASCVD (Atherosclerotic cardiovascular disease) remains a leading cause of morbidity and mortality worldwide, driven by elevated levels of low-density lipoprotein cholesterol (LDL-C) (1). The standard of care includes statins, ezetimibe, and PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) inhibitors to achieve optimal LDL-C (Low d
431 Reached
Complicated case of Osteoarthritis
1850 Reached2 Comments3 Likes
Woman presented with Fever of Unknown Origin
7727 Reached93 Comments19 Likes
How Physicians Should Manage Stress?
35294 Reached152 Comments203 Likes
Case of Pulmonary Embolism with Syncope
544 Reached4 Likes
Switching from Premixed Insulin to Basal Insulin with OADs
1083 Reached2 Comments6 Likes